Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 83003 refers to the measurement of human growth hormone (HGH), also known as somatotropin, through a blood test. Human growth hormone is a peptide hormone produced by the pituitary gland, which plays a crucial role in growth, metabolism, and body composition. It is released in a pulsatile manner throughout the day, meaning that its levels fluctuate rather than remain constant. Due to this variability, random measurements of HGH levels are generally not considered clinically significant, and routine screening for this hormone is not commonly performed. The testing for HGH is primarily indicated in cases where there are clinical concerns regarding growth patterns, such as delayed growth or excessive growth in children and young adults. To conduct this test, a blood sample is collected, typically through a procedure known as venipuncture, which is reported separately. The serum or plasma obtained from the blood sample is then analyzed using a quantitative chemiluminescent immunoassay, a sensitive and specific laboratory technique that quantifies the concentration of HGH in the sample.
© Copyright 2026 Coding Ahead. All rights reserved.
The measurement of human growth hormone (HGH) is indicated in specific clinical scenarios where growth abnormalities are suspected. The following conditions warrant testing:
The procedure for measuring human growth hormone involves several key steps that ensure accurate results. First, a healthcare professional will prepare the patient for the blood draw, which may include explaining the procedure and ensuring the patient is comfortable. Next, a venipuncture is performed to obtain a blood sample. This involves inserting a needle into a vein, typically in the arm, to collect the necessary volume of blood. The blood sample is then placed in a suitable container for processing. Once collected, the serum or plasma is separated from the blood cells through centrifugation. The separated serum or plasma is then subjected to a quantitative chemiluminescent immunoassay, a laboratory technique that utilizes light-emitting reactions to quantify the concentration of HGH in the sample. This method is known for its sensitivity and specificity, allowing for accurate measurement of hormone levels.
After the blood sample has been collected, there are generally no specific post-procedure care requirements for the patient. However, it is advisable for the patient to apply pressure to the venipuncture site to minimize any potential bleeding and to keep the area clean. Patients may resume their normal activities immediately following the procedure. The results of the HGH test will typically be reviewed by the healthcare provider, who will discuss the findings with the patient and determine if any further action or additional testing is necessary based on the results.
| Short Descr | ASSAY GROWTH HORMONE (HGH) | Medium Descr | ASSAY OF GROWTH HORMONE HUMAN | Long Descr | Growth hormone, human (HGH) (somatotropin) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 5 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 76 | Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | Q4 | Service for ordering/referring physician qualifies as a service exemption | QW | Clia waived test | X5 | Diagnostic services requested by another clinician: for reporting services by a clinician who furnishes care to the patient only as requested by another clinician or subsequent and related services requested by another clinician; this modifier is reported for patient relationships that may not be adequately captured by the above alternative categories; reporting clinician service examples include but are not limited to, the radiologist's interpretation of an imaging study requested by another clinician | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2013-01-01 | Changed | Medium Descriptor changed. |
| 2011-01-01 | Changed | Short description changed. |
| Pre-1990 | Added | Code added. |
Get instant expert-level medical coding assistance.